Compare Salesforce Inc (CRM) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Inovio Pharmaceuticals Inc — how do they compare? Salesforce Inc trades at $193.01 (market cap $161.73B), while Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M). The key difference: Salesforce Inc is far larger — about 2058.9× Inovio Pharmaceuticals Inc's market cap, and Salesforce Inc pays a 0.89% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CRM | INO | |
|---|---|---|
Market Cap | $161.73B | $78.55M |
Sector | Technology | Health |
52-Week High | $266.23 | $2.87 |
52-Week Low | $150.12 | $0.66 |
Enterprise Value | $191.77B | $49.56M |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.47, showing minimal daily movement (-0.02%) amid recent market volatility. The stock maintains strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show bullish momentum with support at $196 and resistance at $199, though RSI levels suggest potential overbought conditions. Recent news highlights AI-driven growth opportunities but also sector-wide software stock pressures.
CRM presents a compelling investment case with analyst consensus pointing to 17% upside to the $230.83 price target. Strong cash flow generation ($13.09B operating cash flow) and AI monetization progress support growth, but risks include competitive AI landscape and macroeconomic sensitivity affecting software demand. Institutional sentiment remains positive with 75.78% buy ratings.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
